Compare Aptiv PLC (APTV) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aptiv PLC vs Crispr Therapeutics AG — how do they compare? Aptiv PLC trades at $60.08 (market cap $12.82B), while Crispr Therapeutics AG trades at $53.39 (market cap $5.25B). The key difference: Aptiv PLC is far larger — about 2.4× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| APTV | CRSP | |
|---|---|---|
Market Cap | $12.82B | $5.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $76.78 |
52-Week Low | $52.57 | $44.34 |
Enterprise Value | $19.53B | $3.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
CRISPR Therapeutics (CRSP) trades at $53.35, down 5.31% on the day, with technical indicators showing a bullish trend but mixed earnings performance. The company maintains strong analyst support with a $74.50 consensus price target, despite negative profitability metrics and recent quarterly misses. Recent FDA pediatric approval for Casgevy expands its market potential, though cash flow remains challenged by high operational costs.
Outlook is cautiously optimistic driven by gene-editing leadership and clinical catalysts, but investment carries high risk due to persistent losses, volatile cash flows, and competitive pressures. Upside depends on successful commercialization and pipeline execution, while downside risks include funding needs and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
